

# **Personalized Nutrition: Optimizing Essential Nutrient Status through Testing and Supplementation**

## **Introduction**

Since Casimir Funk first described “vital amines” in 1912, we have seen major improvements in public health through sizable reductions of then commonplace deficiencies [1]. Yet over 100 years later deficiencies in a multitude of macro- and micronutrients (e.g. Vitamin D, E, Omega-3 fatty acids) remain highly prevalent in the general United States (US) population [2]. These nutritional deficiencies have been found to raise the risk of a wide array of health outcomes including the leading causes of death (i.e. cardiovascular diseases, malignant neoplasms, diabetes, and cerebrovascular diseases) [3-10]. Therefore, addressing them is of vital importance to continue to build on the progress we have made thus far, but we also need to move beyond just preventing deficiencies toward the optimization of health and performance for each individual. This dossier will lay out the current state of nutrient intakes in the US, its consequences for human health, and how moving to objective measurements of nutrient status coupled with customized dietary supplement protocols will enable individuals to not just avoid deficiencies but optimize intake for maximal fitness and well-being.

## **Importance for Health, Fitness, and Well-being**

Each essential nutrient has been shown to play a vital role in a wide-array of functions in the human body [11]. Therefore, it is not surprising that deficiency can have severe effects on human health. Poor diet has been found to be the leading risk factor for premature death and

disability in the US, posing a greater risk to health than smoking, hypertension, and obesity [12]. This is based on the fact that nearly half of all cardiometabolic deaths (i.e. heart disease, stroke, and diabetes), over 700,000 annually, are associated with a suboptimal diet (e.g. low fruit, vegetable, and Omega-3 rich seafood intake) [13].

## **Health Benefits of Key Nutrients**

**Long-chain  $\omega$ -3 polyunsaturated fatty acids ( $\omega$ 3-PUFAs)**, in particular, eicosapentaenoic acid (EPA) and docosahexanoic acid (DHA) provide a wide range of health benefits. Higher levels of  $\omega$ 3-PUFAs are associated with lower total mortality, especially death from coronary heart disease [14]. Nearly all U.S. adults (95.7%) have  $\omega$ 3-PUFAs levels below concentrations associated with cardiovascular protection [15].

**Magnesium** is an essential mineral necessary for more than 300 chemical reactions in the human body [16]. Unfortunately, the majority of Americans are not consuming even an adequate amount of magnesium [17]. Low magnesium is linked to an increase risk in coronary heart disease, heart failure, and sudden cardiac death [18, 19]. Higher magnesium intake is associated with a reduced risk of bone fractures, type-2 diabetes, stroke, and death from all causes [20-23].

**Vitamin D** is involved in a multitude of biological functions, including calcium homeostasis, metabolism, and immune function [16]. Deficiency is prevalent (41.6%) among U.S. adults [24]. Poor Vitamin D status (i.e. concentrations too low or high) is associated with an increased risk of headaches [25], liver disease [26], diabetes [27], multiple sclerosis [28], cognitive decline [29, 30], rheumatoid arthritis [31], cancer [32-40], hypertension [41], heart disease [42, 43], bone fracture [44], and death from all causes [45].

Further details of the main functions and effects of deficiency of the nutrients most commonly low in American diets are shown in Table 1.

TABLE 1.


Essential Nutrient	Main Functions	Effects of Deficiency
Omega-3 Fatty Acids	muscle activity, blood clotting, digestion, fertility, and cell division and growth	fatigue, poor memory, dry skin, heart problems, mood swings or depression, and poor circulation
Zinc	growth, brain function, and immune system	slow growth, impotence, hair loss, diarrhea, eye and skin sores, loss of appetite, impaired wound healing, and lower alertness levels
Magnesium	protein synthesis, muscle function, blood glucose control, blood pressure regulation, energy production, synthesis of DNA, RNA, and glutathione, nerve impulse conduction, and normal heart rhythm	loss of appetite, nausea, vomiting, fatigue, weakness, numbness, tingling, muscle contractions and cramps, seizures, personality changes, abnormal heart rhythms, and coronary spasms
Choline	metabolism, cell membranes, memory, mood, muscle control, modulating gene expression, cell membrane signaling, and early brain development	muscle damage, liver damage, and nonalcoholic fatty liver disease
Potassium	build proteins, break down and use carbohydrates, build muscle, maintain normal body growth, Control the electrical activity of the heart, and control the acid-base balance	weak muscles, abnormal heart rhythms, and a rise in blood pressure
Vitamin A	vision, immune system, reproduction, proper function of the heart, lungs and kidneys	blindness

Vitamin C	antioxidant, immune system	fatigue, joint pain, poor wound healing, anemia, and depression
Vitamin D	bone health, nerve and immune function	rickets, bone pain, and muscle weakness
Vitamin E	antioxidant, immune system	peripheral neuropathy, ataxia, skeletal myopathy, retinopathy, and impaired immune response
Vitamin K	bone health and blood clotting	osteoporosis, bleeding, and hemorrhage
Calcium	bone health, nerve and muscle function, and proper release of hormones and enzymes	numbness and tingling in the fingers, convulsions, and abnormal heart rhythms

### **Food and Generic Supplementation Is Not Enough**

The National Health and Nutrition Examination Survey (NHANES) is a yearly survey by the National Center for Health Statistics of the health and nutrition status of a nationally-representative sample of Americans [10]. The most recent reported NHANES intake data (2007-2010, n=16,444) found that the majority of Americans do not meet the Dietary Reference Intakes (DRIs) set by the Institute of Medicine (IOM) for numerous essential nutrients (e.g. vitamins and minerals) [17] (See Figure 1).

**FIGURE 1. Percent of US Population Obtaining Less Than the DRIs for Selected Nutrients**



The majority of American use multivitamin multimineral supplements (MVMM). Users of MVMM supplements have superior intake of a number of essential nutrients compared to diet alone, but still often fail to meet recommended intake levels, while also occasionally exceeding the tolerable upper limit (UL), increasing the risk of toxicity [17, 46].

### **Objective Measurements of Nutrient Status**

In last twenty years, we have seen a paradigm shift across numerous industries toward data-driven management of decision making processes. We are just beginning to see this occur in healthcare where evidence-based and precision medicine are being applied to leverage data to optimize down to the individual patient. We are in dire need of a similar shift to occur within nutrition to close widespread gaps in nutrition and move towards, meaning to optimize nutrient intakes towards individual needs.

The status of essential nutrients in the body is typically estimated by using measurements of nutrient intake as a proxy. This is problematic for a multitude of reasons. 1) The tools used to assess nutrient intake (e.g. food frequency questionnaires (FFQ) and food diaries) require large amounts of effort by individuals in the collection of data [47, 48]. 2) The data collected on dietary intake may not accurately reflect what was consumed due to recall error, day-to-day variations in intake, and biased food inclusion data [49-53]. 3) The nutrient content of a particular food varies considerably due to differences in cultivation and preparation methods [54, 55]. 4) Different forms of a specific nutrient vary in their bioavailability [56-61]. 5) There exists a large inter-individual and intra-individual variability in the absorption, excretion and demand of nutrients [62-64].

Direct measurement of nutrient status via validated biomarkers circumvents the problems associated with accurately measuring nutrient intake, but its use has been limited due to issues pertaining to cost, inconvenience, invasiveness, and the body fluid volumes required for proper analysis.

### **Using Dietary Supplements to Optimize Status**

Once an accurate nutrient status has been determined an effective and safe intervention must then be applied to correct for deficient and suboptimal nutrient levels. The majority of Americans fall short of achieving even adequate nutrient intake through diet alone [17, 46]. Conversely, dietary supplements are well suited for this need.

The U.S. Food and Drug Administration (FDA) defines a dietary supplement as,

*“a product intended for ingestion that contains a "dietary ingredient" intended to add further nutritional value to (supplement) the diet. A "dietary ingredient" may be one, or any combination, of the following substances:*

- *a vitamin*
- *a mineral*
- *an herb or other botanical*
- *an amino acid*
- *a dietary substance for use by people to supplement the diet by increasing the total dietary intake*
- *a concentrate, metabolite, constituent, or extract*

*Dietary supplements may be found in many forms such as tablets, capsules, softgels, gelcaps, liquids, or powders.*

*Some dietary supplements can help ensure that you get an adequate dietary intake of essential nutrients; others may help you reduce your risk of disease.” [65].*

It’s been demonstrated in a multitude of studies that dietary supplements are an effective and safe means of optimizing nutrient status in various populations [66-71]. These improvements in essential nutrient status translate into tangible health benefits for users. For example, supplementation with **ω3-PUFAs** has been shown to reduce triglyceride levels, a biomarker for heart disease, by 20% to 50%. Additionally, supplementation with ω3-PUFAs is beneficial for eye health [72-75], dysmenorrhea [76], weight loss [77], stress [78], blood pressure [79, 80], cognitive function [81-87], mental health [88, 89], liver function [90], inflammation [91, 92], muscle strength [93], muscle mass [94], heart health [95], exercise recovery [96], and anaerobic endurance [97]. **Magnesium** supplementation has been found to convey a wide range of health benefits for users. These include lower blood pressure [98], improved blood glucose levels [99],

improved insulin sensitivity [100-102], stronger bones [103, 104], superior physical performance [105], better sleep [106-108] and reduction of asthmatic symptoms [109-111]. Supplementation with **Vitamin D** results in improved immune function [112, 113], birthweight [114], liver function [115], blood glucose [116, 117], insulin sensitivity [116-118], blood pressure [119, 120], muscle strength & mass [121, 122], cognitive function [123, 124], mood [125-127], sleep [128] injury prevention [129], fat loss [130], and testosterone levels in men [131]. Finally, the benefits of supplementation with **Zinc** have been demonstrated for sleep quality [132], consequences of obesity [133], mood [134], infections [135-137], liver health [138] and acne [139].

### **Safety of Dietary Supplements**

Reasonable concerns have been raised as to the long-term safety of dietary supplement use after a few high-profile studies found that supplementation with certain nutrients resulted in an increase in disease risk (e.g. cancer, stroke) [140, 141]. One important common flaw in the design of these studies has been the lack of an objective measurement of nutrient status. Whereas, trials that have assessed baseline nutrient status have found reductions in death from cancer and all causes with micronutrient supplementation [142-144]. Many micronutrients follow a U-curve for optimal status relative to disease risk, with low and high levels both resulting in compromised physiological functioning [145]. This underscores the importance of measuring nutrient status and its inclusion in all randomized clinical trials (RCTs) evaluating dietary supplementation and health outcomes [145-147].


## **Moving Beyond Generic Supplementation**

To this point a review by Cochrane, that included 56 randomized trials with a total of 95,286 participants, found that Vitamin D supplement use was associated with only a 2% reduction in risk of all-cause mortality [148]. In comparison, a review of 14 studies with a combined total of 62,548 participants found that optimal Vitamin D status was associated with a 31% lower risk of death by any cause when compared to deficient status [149]. This difference between generic supplementation and status has also been seen with Omega-3 fatty acids. A review of 10 studies involving 77,917 participants found that Omega-3 fatty acid supplementation had no significant association with fatal or nonfatal coronary heart disease or any major vascular events [150]. In comparison, risk for cardiovascular mortality was found to be 30% lower with an omega-3 index >8%, in comparison with an omega-3 index of <4% in a meta-analysis of 10 cohort studies [151].

## **Case Study**

To test the concept of optimizing nutrient status through blood-based biomarker guided dietary supplement protocols a 10-week trial was conducted with 48 participants. The seven tested (and accordingly supplemented) biomarkers were alpha-tocopherol, cholecalciferol, copper, magnesium, selenium, zinc and combined EPA and DHA. Participants were retested after four weeks and a final measurement was done six weeks later. Their personalized dietary supplement protocols were adjusted accordingly. 32 participants participated in all three tests (Figure 2). All of them showed at their first testing at minimum one deficit out of the seven tested biomarkers. The median number of deficits was two while 15 participants showed three or more deficits.

After 10 weeks, the median number of deficits declined clearly to one. 7 participants showed no deficit and only four participants were left in the class of three or more deficits. Improvements were seen across all nutrient biomarkers tested.



**Figure 2:** Histogram of the distribution of deficits among 32 participants treated over 10 weeks with the blood-based biomarker guided dietary supplement protocol. The left part shows the distribution at the beginning of the trial, i.e. before supplementation. The right part shows the distribution after 10 weeks.

## Conclusion

Suboptimal intake of essential nutrients is widespread and has a profound impact on human health and performance. Current methods for measuring nutrient status and dietary supplement use fail to meet the needs of individuals. We have demonstrated that nutrient status

can be optimized through the use of personalized dietary supplement protocols (PDSP) that are based on regular testing of blood-based biomarkers. We plan to build on these findings and investigate how PDSPs compare to other current methods for determining dietary supplement recommendations (e.g. survey, broad-category, generic).

## References

1. Kraemer, K., et al., *Introduction: the diverse and essential biological functions of vitamins*. Ann Nutr Metab, 2012. **61**(3): p. 185-91.
2. Blumberg, J.B., et al., *Vitamin and Mineral Intake Is Inadequate for Most Americans: What Should We Advise Patients About Supplements?* J Fam Pract, 2016. **65**(9 Suppl): p. S1-s8.
3. Zheng, W., et al., *Retinol, antioxidant vitamins, and cancers of the upper digestive tract in a prospective cohort study of postmenopausal women*. Am J Epidemiol, 1995. **142**(9): p. 955-60.
4. Albanes, D., et al., *Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study*. Am J Clin Nutr, 1995. **62**(6 Suppl): p. 1427s-1430s.
5. Byers, T. and N. Guerrero, *Epidemiologic evidence for vitamin C and vitamin E in cancer prevention*. Am J Clin Nutr, 1995. **62**(6 Suppl): p. 1385s-1392s.
6. Ebbing, M., et al., *Combined analyses and extended follow-up of two randomized controlled homocysteine-lowering B-vitamin trials*. J Intern Med, 2010. **268**(4): p. 367-82.
7. Elliott, R.B., et al., *A population based strategy to prevent insulin-dependent diabetes using nicotinamide*. J Pediatr Endocrinol Metab, 1996. **9**(5): p. 501-9.
8. Esteve, J., et al., *Diet and cancers of the larynx and hypopharynx: the IARC multi-center study in southwestern Europe*. Cancer Causes Control, 1996. **7**(2): p. 240-52.
9. Negri, E., et al., *Selected micronutrients and oral and pharyngeal cancer*. Int J Cancer, 2000. **86**(1): p. 122-7.
10. Peters, U., et al., *Vitamin E and selenium supplementation and risk of prostate cancer in the Vitamins and lifestyle (VITAL) study cohort*. Cancer Causes Control, 2008. **19**(1): p. 75-87.

11. Otten JJ, H.J., Meyers LD, eds. *Dietary Reference Intakes: The Essential Guide to Nutrient Requirements*. 2006 [cited 2017 April 10th]; Available from: [http://www.nal.usda.gov/fnic/DRI/Essential\\_Guide/DRIEssentialGuideNutReq.pdf](http://www.nal.usda.gov/fnic/DRI/Essential_Guide/DRIEssentialGuideNutReq.pdf).
12. Murray, C.J., et al., *The state of US health, 1990-2010: burden of diseases, injuries, and risk factors*. *Jama*, 2013. **310**(6): p. 591-608.
13. Micha, R., et al., *Association Between Dietary Factors and Mortality From Heart Disease, Stroke, and Type 2 Diabetes in the United States*. *Jama*, 2017. **317**(9): p. 912-924.
14. Mozaffarian, D., et al., *Plasma phospholipid long-chain  $\omega$ -3 fatty acids and total and cause-specific mortality in older adults: A cohort study*. *Annals of Internal Medicine*, 2013. **158**(7): p. 515-525.
15. Murphy, R.A., et al., *Suboptimal plasma long chain n-3 concentrations are common among adults in the United States, NHANES 2003–2004*. *Nutrients*, 2015. **7**(12): p. 10282-10289.
16. Erdman Jr, J.W., I.A. MacDonald, and S.H. Zeisel, *Present knowledge in nutrition*. 2012: John Wiley & Sons.
17. Wallace, T.C., M. McBurney, and V.L. Fulgoni, 3rd, *Multivitamin/mineral supplement contribution to micronutrient intakes in the United States, 2007-2010*. *J Am Coll Nutr*, 2014. **33**(2): p. 94-102.
18. Kieboom, B.C., et al., *Serum magnesium and the risk of death from coronary heart disease and sudden cardiac death*. *Journal of the American Heart Association*, 2016. **5**(1): p. e002707.
19. Kunutsor, S.K., H. Khan, and J.A. Laukkanen, *Serum magnesium and risk of new onset heart failure in men: the Kuopio Ischemic Heart Disease Study*. *European journal of epidemiology*, 2016. **31**(10): p. 1035-1043.
20. Larsson, S. and A. Wolk, *Magnesium intake and risk of type 2 diabetes: a meta-analysis*. *Journal of internal medicine*, 2007. **262**(2): p. 208-214.

21. Larsson, S.C., N. Orsini, and A. Wolk, *Dietary magnesium intake and risk of stroke: a meta-analysis of prospective studies*. The American journal of clinical nutrition, 2012. **95**(2): p. 362-366.
22. Fang, X., et al., *Dietary magnesium intake and the risk of cardiovascular disease, type 2 diabetes, and all-cause mortality: a dose–response meta-analysis of prospective cohort studies*. BMC medicine, 2016. **14**(1): p. 210.
23. Veronese, N., et al., *Dietary magnesium intake and fracture risk: data from a large prospective study*. British Journal of Nutrition, 2017. **117**(11): p. 1570-1576.
24. Forrest, K.Y. and W.L. Stuhldreher, *Prevalence and correlates of vitamin D deficiency in US adults*. Nutr Res, 2011. **31**(1): p. 48-54.
25. Virtanen, J.K., et al., *Low serum 25-hydroxyvitamin D is associated with higher risk of frequent headache in middle-aged and older men*. 2017. **7**: p. 39697.
26. Eliades, M., et al., *Meta-analysis: vitamin D and non-alcoholic fatty liver disease*. Aliment Pharmacol Ther, 2013. **38**(3): p. 246-54.
27. Gorham, E.D., et al., *Lower prediagnostic serum 25-hydroxyvitamin D concentration is associated with higher risk of insulin-requiring diabetes: a nested case-control study*. Diabetologia, 2012. **55**(12): p. 3224-7.
28. Munger, K.L., et al., *Vitamin d status during pregnancy and risk of multiple sclerosis in offspring of women in the finnish maternity cohort*. JAMA Neurology, 2016. **73**(5): p. 515-519.
29. Miller, J.W., et al., *Vitamin d status and rates of cognitive decline in a multiethnic cohort of older adults*. JAMA Neurology, 2015. **72**(11): p. 1295-1303.
30. Feart, C., et al., *Associations of lower vitamin D concentrations with cognitive decline and long-term risk of dementia and Alzheimer's disease in older adults*. Alzheimer's & Dementia, 2017.

31. Hong, Q., et al., *Associations between serum 25-hydroxyvitamin D and disease activity, inflammatory cytokines and bone loss in patients with rheumatoid arthritis*. *Rheumatology*, 2014. **53**(11): p. 1994-2001.
32. Gorham, E.D., et al., *Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis*. *Am J Prev Med*, 2007. **32**(3): p. 210-6.
33. Crew, K.D., et al., *Association between plasma 25-hydroxyvitamin D and breast cancer risk*. *Cancer Prev Res (Phila)*, 2009. **2**(6): p. 598-604.
34. Garland, C.F., et al., *Vitamin D and prevention of breast cancer: pooled analysis*. *J Steroid Biochem Mol Biol*, 2007. **103**(3-5): p. 708-11.
35. Murphy, A.B., et al., *Vitamin D Deficiency Predicts Prostate Biopsy Outcomes*. *Clinical Cancer Research*, 2014. **20**(9): p. 2289-2299.
36. Nyame, Y.A., et al., *Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical Prostatectomy*. *Journal of Clinical Oncology*, 2016. **34**(12): p. 1345-1349.
37. Kristal, A.R., et al., *Plasma Vitamin D and Prostate Cancer Risk: Results from the Selenium and Vitamin E Cancer Prevention Trial*. *Cancer Epidemiology Biomarkers & Prevention*, 2014. **23**(8): p. 1494-1504.
38. Amaral, A.F.S., et al., *Plasma 25-Hydroxyvitamin D3 and Bladder Cancer Risk According to Tumor Stage and FGFR3 Status: A Mechanism-Based Epidemiological Study*. *JNCI: Journal of the National Cancer Institute*, 2012. **104**(24): p. 1897-1904.
39. Yao, S., et al., *Association of serum level of vitamin d at diagnosis with breast cancer survival: A case-cohort analysis in the pathways study*. *JAMA Oncology*, 2017. **3**(3): p. 351-357.
40. Song, M., et al., *Plasma 25-hydroxyvitamin D and colorectal cancer risk according to tumour immunity status*. *Gut*, 2016. **65**(2): p. 296-304.

41. Scragg, R., M. Sowers, and C. Bell, *Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey*. *Am J Hypertens*, 2007. **20**(7): p. 713-9.
42. Muhlestein, J.B., et al., *Abstract 18102: Threshold Effect of Vitamin D Deficiency on Cardiovascular Outcomes: Below What Level of 25(OH) Vitamin D is Cardiovascular Risk Really Increased?* *Circulation*, 2015. **132**(Suppl 3): p. A18102-A18102.
43. Parker, J., et al., *Levels of vitamin D and cardiometabolic disorders: systematic review and meta-analysis*. *Maturitas*, 2010. **65**(3): p. 225-36.
44. Busse, B., et al., *Vitamin D Deficiency Induces Early Signs of Aging in Human Bone, Increasing the Risk of Fracture*. *Science Translational Medicine*, 2013. **5**(193): p. 193ra88-193ra88.
45. Dobnig, H., et al., *Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality*. *Arch Intern Med*, 2008. **168**(12): p. 1340-9.
46. Fulgoni, V.L., 3rd, et al., *Foods, fortificants, and supplements: Where do Americans get their nutrients?* *J Nutr*, 2011. **141**(10): p. 1847-54.
47. Baker, R.C. and D.S. Kirschenbaum, *Self-monitoring may be necessary for successful weight control*. *Behavior Therapy*, 1993. **24**(3): p. 377-394.
48. Burke, L.E., et al., *Ancillary study to the PREFER trial: a descriptive study of participants' patterns of self-monitoring--rationale, design and preliminary experiences*. *Contemp Clin Trials*, 2006. **27**(1): p. 23-33.
49. Schaefer, E.J., et al., *Lack of efficacy of a food-frequency questionnaire in assessing dietary macronutrient intakes in subjects consuming diets of known composition*. *Am J Clin Nutr*, 2000. **71**(3): p. 746-51.

50. Goris, A.H., E.P. Meijer, and K.R. Westerterp, *Repeated measurement of habitual food intake increases under-reporting and induces selective under-reporting*. Br J Nutr, 2001. **85**(5): p. 629-34.
51. Goris, A.H., M.S. Westerterp-Plantenga, and K.R. Westerterp, *Undereating and underrecording of habitual food intake in obese men: selective underreporting of fat intake*. Am J Clin Nutr, 2000. **71**(1): p. 130-4.
52. Livingstone, M.B. and A.E. Black, *Markers of the validity of reported energy intake*. J Nutr, 2003. **133 Suppl 3**: p. 895s-920s.
53. Stone, A.A., et al., *Patient compliance with paper and electronic diaries*. Control Clin Trials, 2003. **24**(2): p. 182-99.
54. Torelm, I., et al., *Variations in Major Nutrients and Minerals Due to Standardized Preparation for Dishes and Raw Ingredients: 1. Losses and Gains in Preparation*. Journal of Food Composition and Analysis, 1996. **9**(4): p. 312-330.
55. Marles, R.J., *Mineral nutrient composition of vegetables, fruits and grains: The context of reports of apparent historical declines*. Journal of Food Composition and Analysis, 2017. **56**: p. 93-103.
56. Firoz, M. and M. Graber, *Bioavailability of US commercial magnesium preparations*. Magnes Res, 2001. **14**(4): p. 257-62.
57. Krebs, N.F., *Bioavailability of dietary supplements and impact of physiologic state: infants, children and adolescents*. J Nutr, 2001. **131**(4 Suppl): p. 1351s-4s.
58. Institute of Medicine Standing Committee on the Scientific Evaluation of Dietary Reference, I., *The National Academies Collection: Reports funded by National Institutes of Health, in Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride*. 1997, National Academies Press (US)

National Academy of Sciences.: Washington (DC).

59. Burton, G.W., et al., *Human plasma and tissue alpha-tocopherol concentrations in response to supplementation with deuterated natural and synthetic vitamin E*. *Am J Clin Nutr*, 1998. **67**(4): p. 669-84.
60. Ranade, V.V. and J.C. Somberg, *Bioavailability and pharmacokinetics of magnesium after administration of magnesium salts to humans*. *Am J Ther*, 2001. **8**(5): p. 345-57.
61. Dyerberg, J., et al., *Bioavailability of marine n-3 fatty acid formulations*. *Prostaglandins Leukot Essent Fatty Acids*, 2010. **83**(3): p. 137-41.
62. Institute of Medicine Panel on Dietary, A. and C. Related, in *Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids*. 2000, National Academies Press (US) Copyright 2000 by the National Academy of Sciences. All rights reserved.: Washington (DC).
63. Borel, P., et al., *A Combination of Single-Nucleotide Polymorphisms Is Associated with Interindividual Variability in Dietary beta-Carotene Bioavailability in Healthy Men*. *J Nutr*, 2015. **145**(8): p. 1740-7.
64. von Schacky, C., *Omega-3 index and cardiovascular health*. *Nutrients*, 2014. **6**(2): p. 799-814.
65. FDA. *What is a dietary supplement?* 2015 06/08/2015 [cited 2017 08/16/2017]; Available from: <https://www.fda.gov/aboutfda/transparency/basics/ucm195635.htm>.
66. van Groningen, L., et al., *Cholecalciferol loading dose guideline for vitamin D-deficient adults*. *Eur J Endocrinol*, 2010. **162**(4): p. 805-11.
67. Grant, W.B. and G.E. Schuitmaker, *Health benefits of higher serum 25-hydroxyvitamin D levels in The Netherlands*. *J Steroid Biochem Mol Biol*, 2010. **121**(1-2): p. 456-8.
68. Flock, M.R., et al., *Determinants of erythrocyte omega-3 fatty acid content in response to fish oil supplementation: a dose-response randomized controlled trial*. *J Am Heart Assoc*, 2013. **2**(6): p. e000513.

69. Patterson, A.C., et al., *Omega-3 polyunsaturated fatty acid blood biomarkers increase linearly in men and women after tightly controlled intakes of 0.25, 0.5, and 1 g/d of EPA + DHA*. *Nutr Res*, 2015. **35**(12): p. 1040-51.
70. Wessells, K.R., et al., *Plasma Zinc Concentration Responds Rapidly to the Initiation and Discontinuation of Short-Term Zinc Supplementation in Healthy Men*. *The Journal of Nutrition*, 2010.
71. Lowe, N.M., et al., *The relationship between zinc intake and serum/plasma zinc concentration in adults: a systematic review and dose-response meta-analysis by the EURRECA Network*. *Br J Nutr*, 2012. **108**(11): p. 1962-71.
72. Souied, E.H., et al., *Oral docosahexaenoic acid in the prevention of exudative age-related macular degeneration: the Nutritional AMD Treatment 2 study*. *Ophthalmology*, 2013. **120**(8): p. 1619-31.
73. Epitropoulos, A.T., et al., *Effect of Oral Re-esterified Omega-3 Nutritional Supplementation on Dry Eyes*. *Cornea*, 2016. **35**(9): p. 1185-91.
74. Kangari, H., et al., *Short-term consumption of oral omega-3 and dry eye syndrome*. *Ophthalmology*, 2013. **120**(11): p. 2191-6.
75. Kawakita, T., et al., *Effects of dietary supplementation with fish oil on dry eye syndrome subjects: randomized controlled trial*. *Biomedical Research*, 2013. **34**(5): p. 215-220.
76. Hosseinlou, A., et al., *The effects of fish oil capsules and vitamin B1 tablets on duration and severity of dysmenorrhea in students of high school in Urmia-Iran*. *Glob J Health Sci*, 2014. **6**(7 Spec No): p. 124-9.
77. Munro, I.A. and M.L. Garg, *Prior supplementation with long chain omega-3 polyunsaturated fatty acids promotes weight loss in obese adults: a double-blinded randomised controlled trial*. *Food Funct*, 2013. **4**(4): p. 650-8.

78. Carter, J.R., et al., *Fish oil and neurovascular reactivity to mental stress in humans*. Am J Physiol Regul Integr Comp Physiol, 2013. **304**(7): p. R523-30.
79. Miller, P.E., M. Van Elswyk, and D.D. Alexander, *Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and blood pressure: a meta-analysis of randomized controlled trials*. American journal of hypertension, 2014. **27**(7): p. 885-896.
80. Campbell, F., et al., *A systematic review of fish-oil supplements for the prevention and treatment of hypertension*. Eur J Prev Cardiol, 2013. **20**(1): p. 107-20.
81. Lee, L.K., et al., *Docosahexaenoic acid-concentrated fish oil supplementation in subjects with mild cognitive impairment (MCI): a 12-month randomised, double-blind, placebo-controlled trial*. Psychopharmacology, 2013. **225**(3): p. 605-612.
82. Lin, P.Y., et al., *A meta-analytic review of polyunsaturated fatty acid compositions in dementia*. J Clin Psychiatry, 2012. **73**(9): p. 1245-54.
83. van der Wurff, I.S., et al., *Association between Blood Omega-3 Index and Cognition in Typically Developing Dutch Adolescents*. Nutrients, 2016. **8**(1).
84. Witte, A.V., et al., *Long-chain omega-3 fatty acids improve brain function and structure in older adults*. Cereb Cortex, 2014. **24**(11): p. 3059-68.
85. Stonehouse, W., et al., *DHA supplementation improved both memory and reaction time in healthy young adults: a randomized controlled trial*. Am J Clin Nutr, 2013. **97**(5): p. 1134-43.
86. Narendran, R., et al., *Improved working memory but no effect on striatal vesicular monoamine transporter type 2 after omega-3 polyunsaturated fatty acid supplementation*. PLoS One, 2012. **7**(10): p. e46832.
87. Bo, Y., et al., *The n-3 Polyunsaturated Fatty Acids Supplementation Improved the Cognitive Function in the Chinese Elderly with Mild Cognitive Impairment: A Double-Blind Randomized Controlled Trial*. Nutrients, 2017. **9**(1): p. 54.

88. Sarris, J., D. Mischoulon, and I. Schweitzer, *Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression*. J Clin Psychiatry, 2012. **73**(1): p. 81-6.
89. Kiecolt-Glaser, J.K., et al., *Omega-3 supplementation lowers inflammation and anxiety in medical students: a randomized controlled trial*. Brain Behav Immun, 2011. **25**(8): p. 1725-34.
90. Parker, H.M., et al., *Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis*. J Hepatol, 2012. **56**(4): p. 944-51.
91. Miles, E.A. and P.C. Calder, *Influence of marine n-3 polyunsaturated fatty acids on immune function and a systematic review of their effects on clinical outcomes in rheumatoid arthritis*. Br J Nutr, 2012. **107 Suppl 2**: p. S171-84.
92. Kiecolt-Glaser, J.K., et al., *Omega-3 Supplementation Lowers Inflammation in Healthy Middle-Aged and Older Adults: A Randomized Controlled Trial*. Brain, Behavior, and Immunity, 2012. **26**(6): p. 988-995.
93. Rodacki, C.L., et al., *Fish-oil supplementation enhances the effects of strength training in elderly women*. Am J Clin Nutr, 2012. **95**(2): p. 428-36.
94. Smith, G.I., et al., *Fish oil-derived n-3 PUFA therapy increases muscle mass and function in healthy older adults*. Am J Clin Nutr, 2015. **102**(1): p. 115-22.
95. Maki, K.C., et al., *Use of supplemental long-chain omega-3 fatty acids and risk for cardiac death: An updated meta-analysis and review of research gaps*. J Clin Lipidol, 2017.
96. Mickleborough, T.D., et al., *The effects PCSO-524(R), a patented marine oil lipid and omega-3 PUFA blend derived from the New Zealand green lipped mussel (*Perna canaliculus*), on indirect markers of muscle damage and inflammation after muscle damaging exercise in untrained men: a randomized, placebo controlled trial*. J Int Soc Sports Nutr, 2015. **12**: p. 10.

97. Gravina, L., et al., *n-3 Fatty Acid Supplementation During 4 Weeks of Training Leads to Improved Anaerobic Endurance Capacity, but not Maximal Strength, Speed, or Power in Soccer Players*. *Int J Sport Nutr Exerc Metab*, 2017. **27**(4): p. 305-313.
98. Zhang, X., et al., *Effects of Magnesium Supplementation on Blood Pressure: A Meta-Analysis of Randomized Double-Blind Placebo-Controlled Trials*. *Hypertension*, 2016. **68**(2): p. 324-33.
99. Guerrero-Romero, F., et al., *Oral magnesium supplementation improves glycaemic status in subjects with prediabetes and hypomagnesaemia: a double-blind placebo-controlled randomized trial*. *Diabetes & metabolism*, 2015. **41**(3): p. 202-207.
100. Mooren, F., et al., *Oral magnesium supplementation reduces insulin resistance in non-diabetic subjects—a double-blind, placebo-controlled, randomized trial*. *Diabetes, Obesity and Metabolism*, 2011. **13**(3): p. 281-284.
101. Rodriguez-Moran, M. and F. Guerrero-Romero, *Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial*. *Diabetes Care*, 2003. **26**(4): p. 1147-52.
102. Guerrero-Romero, F. and M. Rodriguez-Moran, *Magnesium improves the beta-cell function to compensate variation of insulin sensitivity: double-blind, randomized clinical trial*. *Eur J Clin Invest*, 2011. **41**(4): p. 405-10.
103. Ryder, K.M., et al., *Magnesium intake from food and supplements is associated with bone mineral density in healthy older white subjects*. *Journal of the American Geriatrics Society*, 2005. **53**(11): p. 1875-1880.
104. Carpenter, T.O., et al., *A randomized controlled study of effects of dietary magnesium oxide supplementation on bone mineral content in healthy girls*. *J Clin Endocrinol Metab*, 2006. **91**(12): p. 4866-72.

105. Veronese, N., et al., *Effect of oral magnesium supplementation on physical performance in healthy elderly women involved in a weekly exercise program: a randomized controlled trial*. The American journal of clinical nutrition, 2014. **100**(3): p. 974-981.
106. Hornyak, M., et al., *Magnesium therapy for periodic leg movements-related insomnia and restless legs syndrome: an open pilot study*. Sleep, 1998. **21**(5): p. 501-505.
107. Nielsen, F.H., L.K. Johnson, and H. Zeng, *Magnesium supplementation improves indicators of low magnesium status and inflammatory stress in adults older than 51 years with poor quality sleep*. Magnes Res, 2010. **23**(4): p. 158-68.
108. Held, K., et al., *Oral Mg(2+) supplementation reverses age-related neuroendocrine and sleep EEG changes in humans*. Pharmacopsychiatry, 2002. **35**(4): p. 135-43.
109. Bede, O., et al., *Urinary magnesium excretion in asthmatic children receiving magnesium supplementation: a randomized, placebo-controlled, double-blind study*. Magnes Res, 2003. **16**(4): p. 262-70.
110. Kazaks, A.G., et al., *Effect of oral magnesium supplementation on measures of airway resistance and subjective assessment of asthma control and quality of life in men and women with mild to moderate asthma: a randomized placebo controlled trial*. J Asthma, 2010. **47**(1): p. 83-92.
111. Gontijo-Amaral, C., et al., *Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial*. Eur J Clin Nutr, 2007. **61**(1): p. 54-60.
112. Martineau, A.R., et al., *Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data*. BMJ, 2017. **356**.
113. Bergman, P., et al., *Vitamin D supplementation to patients with frequent respiratory tract infections: a post hoc analysis of a randomized and placebo-controlled trial*. BMC Research Notes, 2015. **8**(1): p. 391.

114. Gernand, A.D., et al., *Maternal serum 25-hydroxyvitamin D and measures of newborn and placental weight in a U.S. multicenter cohort study*. J Clin Endocrinol Metab, 2013. **98**(1): p. 398-404.
115. Papapostoli, I., F. Lammert, and C.S. Stokes, *Effect of Short-Term Vitamin D Correction on Hepatic Steatosis as Quantified by Controlled Attenuation Parameter (CAP)*. J Gastrointestin Liver Dis, 2016. **25**(2): p. 175-81.
116. Sun, X., et al., *Vitamin D supplementation reduces insulin resistance in Japanese adults: a secondary analysis of a double-blind, randomized, placebo-controlled trial*. Nutr Res, 2016. **36**(10): p. 1121-1129.
117. Sorkin, J.D., et al., *Evidence for Threshold Effects of 25-Hydroxyvitamin D on Glucose Tolerance and Insulin Resistance in Black and White Obese Postmenopausal Women*. The Journal of Nutrition, 2014. **144**(5): p. 734-742.
118. Nazarian, S., et al., *Vitamin D3 supplementation improves insulin sensitivity in subjects with impaired fasting glucose*. Transl Res, 2011. **158**(5): p. 276-81.
119. Chen, W.R., et al., *Vitamin D and nifedipine in the treatment of Chinese patients with grades I-II essential hypertension: a randomized placebo-controlled trial*. Atherosclerosis, 2014. **235**(1): p. 102-9.
120. Witham, M.D., M.A. Nadir, and A.D. Struthers, *Effect of vitamin D on blood pressure: a systematic review and meta-analysis*. J Hypertens, 2009. **27**(10): p. 1948-54.
121. Cangussu, L.M., et al., *Effect of vitamin D supplementation alone on muscle function in postmenopausal women: a randomized, double-blind, placebo-controlled clinical trial*. Osteoporos Int, 2015. **26**(10): p. 2413-21.

122. Tomlinson, P.B., C. Joseph, and M. Angioi, *Effects of vitamin D supplementation on upper and lower body muscle strength levels in healthy individuals. A systematic review with meta-analysis.* J Sci Med Sport, 2015. **18**(5): p. 575-80.
123. Pettersen, J.A., *Does high dose vitamin D supplementation enhance cognition?: A randomized trial in healthy adults.* Exp Gerontol, 2017. **90**: p. 90-97.
124. Dean, A.J., et al., *Effects of vitamin D supplementation on cognitive and emotional functioning in young adults--a randomised controlled trial.* PLoS One, 2011. **6**(11): p. e25966.
125. Penckofer, S., et al., *Vitamin D Supplementation Improves Mood in Women with Type 2 Diabetes.* J Diabetes Res, 2017. **2017**: p. 8232863.
126. Vaziri, F., et al., *A randomized controlled trial of vitamin D supplementation on perinatal depression: in Iranian pregnant mothers.* BMC Pregnancy and Childbirth, 2016. **16**: p. 239.
127. Hogberg, G., et al., *Depressed adolescents in a case-series were low in vitamin D and depression was ameliorated by vitamin D supplementation.* Acta Paediatr, 2012. **101**(7): p. 779-83.
128. Majid, M.S., et al., *The effect of vitamin D supplement on the score and quality of sleep in 20-50 year-old people with sleep disorders compared with control group.* Nutr Neurosci, 2017: p. 1-9.
129. Shindle, M.K., et al., *Vitamin D status in a professional American football team.* Medicine & Science in Sports & Exercise, 2011. **43**(5): p. 511.
130. Salehpour, A., et al., *A 12-week double-blind randomized clinical trial of vitamin D(3) supplementation on body fat mass in healthy overweight and obese women.* Nutr J, 2012. **11**: p. 78.
131. Pilz, S., et al., *Effect of vitamin D supplementation on testosterone levels in men.* Horm Metab Res, 2011. **43**(3): p. 223-5.
132. Gholipour Baradari, A., et al., *The Effect of Zinc Supplementation on Sleep Quality of ICU Nurses: A Double Blinded Randomized Controlled Trial.* Workplace Health Saf, 2018. **66**(4): p. 191-200.

133. Kelishadi, R., et al., *Effect of zinc supplementation on markers of insulin resistance, oxidative stress, and inflammation among prepubescent children with metabolic syndrome*. *Metab Syndr Relat Disord*, 2010. **8**(6): p. 505-10.
134. Solati, Z., et al., *Zinc monotherapy increases serum brain-derived neurotrophic factor (BDNF) levels and decreases depressive symptoms in overweight or obese subjects: a double-blind, randomized, placebo-controlled trial*. *Nutr Neurosci*, 2015. **18**(4): p. 162-8.
135. Prasad, A.S., et al., *Zinc supplementation decreases incidence of infections in the elderly: effect of zinc on generation of cytokines and oxidative stress*. *Am J Clin Nutr*, 2007. **85**(3): p. 837-44.
136. Prasad, A.S., et al., *Duration and severity of symptoms and levels of plasma interleukin-1 receptor antagonist, soluble tumor necrosis factor receptor, and adhesion molecules in patients with common cold treated with zinc acetate*. *J Infect Dis*, 2008. **197**(6): p. 795-802.
137. Prasad, A.S., et al., *Duration of symptoms and plasma cytokine levels in patients with the common cold treated with zinc acetate. A randomized, double-blind, placebo-controlled trial*. *Ann Intern Med*, 2000. **133**(4): p. 245-52.
138. Somi, M.H., et al., *Effects of low dose zinc supplementation on biochemical markers in non-alcoholic cirrhosis: a randomized clinical trial*. *Arch Iran Med*, 2012. **15**(8): p. 472-6.
139. Dreno, B., et al., *Multicenter randomized comparative double-blind controlled clinical trial of the safety and efficacy of zinc gluconate versus minocycline hydrochloride in the treatment of inflammatory acne vulgaris*. *Dermatology*, 2001. **203**(2): p. 135-40.
140. de Abajo, F.J., et al., *Risk of Ischemic Stroke Associated With Calcium Supplements With or Without Vitamin D: A Nested Case-Control Study*. *J Am Heart Assoc*, 2017. **6**(5).
141. Klein, E.A., et al., *Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)*. *Jama*, 2011. **306**(14): p. 1549-56.

142. Blot, W.J., et al., *Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population*. J Natl Cancer Inst, 1993. **85**(18): p. 1483-92.
143. Hartman, T.J., et al., *Association of the B-vitamins pyridoxal 5'-phosphate (B(6)), B(12), and folate with lung cancer risk in older men*. Am J Epidemiol, 2001. **153**(7): p. 688-94.
144. Johansson, M., et al., *Serum B vitamin levels and risk of lung cancer*. Jama, 2010. **303**(23): p. 2377-85.
145. Morris, M.C. and C.C. Tangney, *A potential design flaw of randomized trials of vitamin supplements*. Jama, 2011. **305**(13): p. 1348-9.
146. Goyal, A., M.B. Terry, and A.B. Siegel, *Serum antioxidant nutrients, vitamin A, and mortality in U.S. Adults*. Cancer Epidemiol Biomarkers Prev, 2013. **22**(12): p. 2202-11.
147. Mayne, S.T., L.M. Ferrucci, and B. Cartmel, *Lessons learned from randomized clinical trials of micronutrient supplementation for cancer prevention*. Annu Rev Nutr, 2012. **32**: p. 369-90.
148. Bjelakovic, G., et al., *Vitamin D supplementation for prevention of mortality in adults*. Cochrane Database Syst Rev, 2014(1): p. Cd007470.
149. Zittermann, A., et al., *Vitamin D deficiency and mortality risk in the general population: a meta-analysis of prospective cohort studies*. Am J Clin Nutr, 2012. **95**(1): p. 91-100.
150. Aung, T., et al., *Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77917 Individuals*. JAMA Cardiol, 2018. **3**(3): p. 225-234.
151. Harris, W.S., L. Del Gobbo, and N.L. Tintle, *The Omega-3 Index and relative risk for coronary heart disease mortality: Estimation from 10 cohort studies*. Atherosclerosis, 2017. **262**: p. 51-54.